Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
LOS ANGELES, April 27, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD) concerning possible violations of federal securities laws between July 7, 2016 and April 9, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired the Company’s shares during the Class Period should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. When this information was released, the Company’s stock price decreased materially, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
